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Point‑of‑care SARS‑CoV‑2 
serological assays for enhanced 
case finding in a UK inpatient 
population
S. J. C. Pallett1,2, S. J. Denny2,3, A. Patel2, E. Charani4, N. Mughal2,3,4, J. Stebbing5, 
G. W. Davies2 & L. S. P. Moore2,3,4*
Severe Acute Respiratory Syndrome coronavirus 2 (SARS‑CoV‑2) has become a global pandemic. Case 
identification is currently made by real‑time polymerase chain reaction (PCR) during the acute phase 
and largely restricted to healthcare laboratories. Serological assays are emerging but independent 
validation is urgently required to assess their utility. We evaluated five different point‑of‑care 
(POC) SARS‑CoV‑2 antibody test kits against PCR, finding concordance across the assays (n = 15). 
We subsequently tested 200 patients using the OrientGene COVID‑19 IgG/IgM Rapid Test Cassette 
and find a sensitivity of 74% in the early infection period (day 5–9 post symptom onset), with 100% 
sensitivity not seen until day 13, demonstrating inferiority to PCR testing in the infectious period. 
Negative rate was 96%, but in validating the serological tests uncovered potential false‑negatives 
from PCR testing late‑presenting cases. A positive predictive value (PPV) of 37% in the general 
population precludes any use for general screening. Where a case definition is applied however, the 
PPV is substantially improved (95.4%), supporting use of serology testing in carefully targeted, high‑
risk populations. Larger studies in specific patient cohorts, including those with mild infection are 
urgently required to inform on the applicability of POC serological assays to help control the spread of 
SARS‑CoV‑2 and improve case finding of patients that may experience late complications.
On 31 December 2019 alarm over a pneumonia-like viral illness caused by an unknown pathogen was first 
raised to the World Health Organisation. A genome sequence for the presumed causative agent since designated 
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) was publically released by early January  20201, 
enabling molecular diagnostics to be rapidly developed. SARS-CoV-2 has now extensively spread and been 
designated a global pandemic.
Clinical presentation ranges from mild upper respiratory tract infection to severe pneumonia with acute 
respiratory distress  syndrome2. The burden on healthcare systems has been devastating, particularly for inten-
sive care  services3. As of April 2020 there had been over 1 million cases with a case fatality ratio varying from 1 
to 6%4. The true case fatality ratio is thought to be closer to 1–2% with a considerable number of unrecognised 
subclinical cases likely to be found in the community. Without the availability of serological testing, this has 
proven very difficult to accurately  assess2. While real-time PCR is available during the acute infection it is limited 
by laboratory and skilled operator  requirements5, and can only be used early in the symptomatic clinical course. 
Serologic testing for SARS-CoV-2 offers the potential for enhanced case finding for patients presenting later in 
the disease course, as well as enabling serosurveillance at a much wider level than molecular diagnostics allow.
Multiple lateral flow serology tests have recently been developed for rapid, point-of-care (POC) use, provid-
ing qualitative results within 15 min. Whilst many of these devices have their initial development in China, they 
require verification in the cohort intended for use before extensive uptake. We take five of these POC kits and 
evaluate their suitability and potential utility for use in a western European population that had experienced 
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symptoms in line with the Public Health England (PHE) case definition for  testing6 against the current gold 
standard of RT-PCR. We go on to take one assay forward for further evaluation (OrientGene COVID-19 IgG/
IgM Rapid Test Cassettes), completing 200 assays and commenting on test performance metrics in a UK inpa-
tient population.
Results
Validation of serology POC tests. Fifteen patients (mean age 69 years, range 52–85 years, 8/15 female) 
underwent testing with each of the five assays. All patients had RT-PCR testing conducted between 2 and 10 days 
from symptom onset, except patient 11 who was first tested at day 13 (Fig. 1; chronological relationship between 
symptom onset, presentation to secondary care, RT-PCR testing and antibody testing). Of the 75 tests, all were 
included in the final analysis. No test kit failures were observed. The control line was visible on all 75 test kits 
run at 15 min post-sampling.
Validation PCR positive patients. Ten patients with positive RT-PCR SARS-CoV-2 results were tested 
with each of the five assays (total = 50). The same seven patients were reactive across all five serology tests (35/50; 
Fig. 1) and were in concordance for reactive tests from day 8 onwards. One further patient was reactive using the 
SARS-CoV-2 total antibody test (Wantai) (1/50), reactive for IgM only with the COVID-19 split IgG/IgM Rapid 
Test Cassette (OrientGene) and SARS-CoV-2 split IgM/IgG One Step Rapid Test Device (Encode) at day 6 (2/50) 
but negative for the other two assays (2/50). The remaining tests were unreactive, all of which were at an earlier 
stage post symptom onset of day 5 or 6 (10/60).
Validation PCR negative patients. Five patients with a minimum of one negative RT-PCR result (range 
1–4 negative PCRs) were tested with each of the five assays (total = 25). The same four patients were unreactive 
across all five serology tests (20/25). The fifth patient was reactive using all five assays (5/25).
OrientGene COVID‑19 IgG/IgM rapid test cassette analysis. 200 patients (mean age 61 years, range 
32–93 years, 43% female) underwent testing. All 200 assays were included in the final analysis. Two test kit 
failures were observed (failure of solution to ascend chromotography paper), of which both were repeated with 
subsequent valid reads.
OrientGene analysis PCR positive patients. 150 patients had positive RT-PCR SARS-CoV-2 results 
(Fig. 2). A total of 130/150 OrientGene COVID-19 split IgG/IgM assays were reactive. Of those tested at 5–9 days 
post-symptom onset (n = 50) 37/50 were reactive (74% sensitivity, 95% confidence interval [CI] 59.7 to 85.4%). 
At days 10–14 post-symptom onset (n = 50), 43/50 were reactive (86% sensitivity, 95% CI 73.3 to 94.2%). At 
greater than 14 days post-symptom onset (n = 50) there were 50/50 reactive assays (100% sensitivity, 95% CI 
92.9 to 100%) (Table 1b,c). Tests were uniformly reactive from day 13 onwards (n = 67) (Fig. 3). Reactive assays 
Figure 1.  Chronological relationship between onset of symptoms and test results. Results of PCR vs five 
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were observed with a single reactive IgM line (6/130), single reactive IgG line (5/130), or both reactive IgM and 
IgG lines (119/130) (Table 1a). The longest period post-symptom onset tested was at 40 days and demonstrated 
persistence of both an IgM and IgG reactive line (Fig. 3).
OrientGene analysis PCR negative patients. 50 patients that were presumed negative (admitted with 
no symptom or radiological features of SARS-CoV-2 infection and with a negative SARS-CoV-2 PCR test) were 
included (Fig. 2). Patients were acute admissions under trauma and orthopaedics (12), general surgery (19), 
burns and plastic surgery (8) and general medicine specialties (11; gout (1), complications of diabetes (2), fol-
lowing a fall (3), palpitations (1), alcohol withdrawal (2), chest pain (1) and gastroenteritis (1)). Assays on 48/50 
negative patients were completely unreactive (negative rate 96%, 95% CI 86.3 to 99.5%). Two patients demon-
strated a reactive IgM line only.
Figure 2.  Flowchart demonstrating patient recruitment and subsequent SARS-CoV-2 PCR and serological 
status. All recruited individuals were inpatients at the time of testing. All patients had a screening chest x-ray as 
part of the admission protocol and specific comments on findings, or absence of, associated with SARS-CoV-2 
infection. None of the 50 negative arm patients had radiological findings consistent with probably SARS-CoV-2 
infection. All patients in the positive arm were considered to have moderate to severe SARS-CoV-2 infection, 
and had radiological findings that were in keeping with probable SARS-CoV-2 infection.
Table 1.  OrientGene point-of-care SARS-CoV-2 serology testing (n = 200) among inpatients, March–April 
2020, London. (a) Control, IgM, and IgG line detection across different symptom durations, where C control 
line only, G IgM line observed, M IgM line observed. (b) Sensitivity and negative rate across all 200 assays. (c) 
Sensitivity and negative rate across different symptom durations.
SARS-CoV-2 PCR Days post symptom onset
OrientGene serology results
CXM CGX CGM CXX
(a)
Positive
5–9 4 3 30 13
10–14 1 2 40 7
 > 14 1 0 49 0
Negative N/A
2 0 0 48
8 5 119 68
SARS-CoV-2 PCR positive SARS-CoV-2 PCR negative
(b)
OrientGene test positive 130 2
OrientGene test negative 20 48
Whole cohort sensitivity = 87%; negative rate = 96% (n = 200)
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POC assay performance characteristics. Re-testing of patients with reactive assays with a second test 
had demonstrable reproducibility (n = 3). The tests with too little blood (n = 1), or too much blood (n = 1) failed, 
with no reactivity seen on test lines in the former and no reactivity in test or control lines in the latter.
Where an estimated prevalence of 2.7% in the general population is applied the positive predictive value 
(PPV) is calculated at 37%7, negative predictive value (NPV) 99.6%. When calculated for suspected cases meet-
ing the PHE criteria using a prevalence of 48% (86/177 positive in those tested across the week of 23 March–29 
March 2020) in our inpatient population at the same time point there is a PPV of 95.4% and NPV of 88.4%.
Discussion
Serologic testing for SARS-CoV-2 has the potential to augment control strategies by improving our understand-
ing of the true burden of infection during the current pandemic. While the small number of tests performed (in 
comparison to the estimated UK prevalence of 2.7% as of 28th March 2020)6 during this early validation study 
makes it difficult to draw high-powered conclusions, the results offer useful insights into the potential utility of 
POC serological testing at this early stage in the pandemic response. Key concerns exist around the reliability of 
serology testing and identifying any potential time points for appropriate use.
Our study raises significant concern for the reliance on serology testing in the initial infection phase. Analysis 
of the larger 200 patient cohort shows that when the initial patient group (days 5–9 post symptom onset) are 
considered, there is a sensitivity of 74%, with the potential therefore to miss a significant number of positive cases 
during their most infectious  period7. Practically, if considering potential use of the assays in the early phase of 
infection (as suggested by some of the assay manufacturers, and during which period self-isolation is advised by 
PHE) the sensitivity drops to 66% (n = 32). It is not until the end of the second week from symptom onset that 
the test appears to demonstrate a more practical use. In the greater than 14 day since symptom onset group there 
was 100% sensitivity. The latest false negative was demonstrated on day 12 with reactive results produced in all 
tests taken thereafter (n = 67) suggesting that there could be real utility in POC serology from 14 days onwards. 
Where PCR testing is currently limited due to demand this could therefore have a potential role in testing those 
healthcare workers who have already self-isolated because of possible infection in the last few months. In addi-
tion the assay may have a role in community testing where timelines in patients with mild symptoms already 
self-isolating would be less time critical. A role is not seen however for an impact on public health guidance 
around self-isolation practices during the infectious period. A PPV of 37% for the general population precludes 
any consideration of deployment of serology testing for general screening. Where a case definition is applied 
however, as is required for meeting the PCR testing criteria, the PPV is substantially improved (95.4%) and sup-
ports use of serology testing in carefully targeted populations. While limited to detection in targeted populations 
this would still enable a far better understanding of the infection-fatality ratio then we are currently able to draw 
from predominantly hospital cases of infection.
At a time when there is considerable pressure on healthcare services it is important to be able to identify 
SARS-CoV-2 negative patients, streamline pathways and help guide clinical decision making for differential 
diagnoses. In the larger, second half of the study, serological testing of ‘negative’ patients (n = 50) demonstrated 
a negative rate of 96% suggesting an additional role in supporting suspected inpatients that return negative PCR 
Figure 3.  OrientGene point-of-care SARS-CoV-2 serology testing (n = 200) among inpatients, March–April 
2020, London. Assay results against the number of assays performed on each day post-symptom onset.
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results. In particular this could help guide management of patients presenting outside the reliable detection 
period for PCR swabbing of the upper respiratory  tract7. If the ‘negative’ patients across both halves of the study 
(total n = 55) are considered, three had reactive results, with only one demonstrating a reactive IgG line. Given 
our selection of this ‘negative’ patient from among those who had an a priori clinical suspicion of SARS-CoV-2 
infection but who were PCR negative, it is possible or indeed likely that these represented missed cases of SARS-
CoV-2. This particular patient presented in extremis with acute respiratory distress-like features (Fig. 1, patient 
11). Where PCR is currently the only diagnostic test in use, the ‘missed’ cases tested with PCR raise the possibility 
of supporting diagnostic capability via serology testing in specific cases. In particular, this may be beneficial in 
patients presenting during the late phase where PCR is less sensitive or where there is a protracted or unclear 
history of onset and clinical suspicion is supported by other findings, such as typical radiological changes.
When considering use in outpatient settings, it is vital that a suitable time period is established for a true nega-
tive result. Our study suggests that this point is to be found at day 13 post-symptom onset at the earliest, limiting 
the utility of these assays in enabling return to work or in informing additional self-isolation practices. There is 
however a real role in helping to identify those healthcare workers and so better understand overall the overall 
burden of infection in high-risk groups, that have been through a self-isolation period with presumptive infection 
supported by concomitant reinforcement of advice around the stringent infection, prevention control measures.
If widely employed, demand on suppliers for POC serological assays will be high and interchangeability of 
kits may therefore be required. The plurality of kits currently available makes it difficult to comment on indi-
vidual assay performance at this early stage and it is therefore essential to evaluate performance across the range 
of kits available both against the gold standard (PCR) as well as against each other as soon as possible. Of the 
five different assays we evaluated, there was direct concordance for detection of SARS-CoV-2 infection across 
seven of the PCR positive patients (35/38 of reactive results). All five kits failed to detect SARS-CoV-2 infection 
from two known early positive samples taken at day 5 and day 6 post-symptom onset. Our findings suggested 
that results consistently appeared reactive from only day 8 post-onset of symptoms onwards across all five kits 
(extended to day 14 onwards in the larger second half of our evaluation). We cite ongoing concern for their reli-
ability during that early period and the significant impact that missing a positive infection could have on public 
health control measures.
All POC serology kits are qualitative and while there was general correlation with colour intensity as time 
from symptom onset increased, variance in intensity of positive results was noted. The test kit instructions com-
ment clearly on expectation for varied colour intensity of positive results and advise that even very weak colour 
should be considered to be reactive. When considering the practicalities of widespread testing, clear instruc-
tion on interpretation will have to feature in standard operating procedures and should allow for comment on 
interpreting the colour intensity of reactive samples. Antibody levels analysed via validated laboratory-based 
enzyme-linked immunosorbent assay (ELISA) platforms have suggested higher levels following severe compared 
to mild infections and cohort studies will now be needed to evaluate the extent of reliability for POC serology 
testing in mild community  infection8.
Little in the way of conclusion can be drawn from the five test kits used to explore concerns around end-user 
difficulties. Re-sampling of reactive patients provided re-producible results and further investigation should be 
conducted to comment on reproducibility of POC serology kits. Of significant use however is the observation 
that tests completed against manufacturer protocol by transferring either too little, or too much whole blood into 
the well resulted in failure. Those tasked with carrying out testing must complete the test as instructed using the 
marked pipette in order to have reliable results. Failure to register a control line in these cases should avoid the 
mistake of reporting an inappropriate false result.
When comparing the utility of the SARS-CoV-2 split IgM/IgG tests (Core tests, OrientGene, VivaDiag, 
Encode) versus the SARS-CoV-2 total antibody test (Wantai), the former have a potential capacity to provide 
greater information. Of the total reactive tests in the 200 cohort study (n = 130), 119 showed both IgM and IgG 
reactivity. There were 11 reactive samples that differentiated between IgM (6/130) and IgG (5/130) (Table 1a). 
IgM/IgG reactivity was seen as early as day 5 post-symptom onset and as late as day 40 but there was insignificant 
data to make conclusions on the IgM/IgG relationship in SARS-CoV-2 infection at this stage. At present we have 
very little understanding of the immunological response to SARS-CoV-2 and the timeline for which IgM is likely 
to remain detectable. Of note, subsequent work has demonstrated follow-up testing of IgM only results with 
laboratory-based anti-nucleocapsid and anti-spike (anti-receptor binding domain) immunoassays shows only 
limited seroconversion of these cases to IgG and should therefore be interpreted with  caution9. If SARS-CoV-2 
has ongoing transmission among humans, detection of IgM may then have a role in detecting sentinel cases 
during subsequent periods of infection. Staged evaluation of IgM and IgG relationship in known SARS-CoV-2 
positive patients over a prolonged period will be required to inform on the potential additional benefits, if any, 
of splitting out the IgM and IgG reactivity in POC assays.
Cross-reactivity leading to false positive results is of considerable concern, both with human seasonal coro-
naviruses and zoonotic beta-coronaviruses, including SARS and MERS. Okba et al. used serum samples from 3 
SARS-CoV-2 positive patients and found cross-reactivity with the SARS-1 S and S1 proteins, and less so but also 
with MERS-CoV S  protein8. The S1 protein appears to be more specific to the SARS coronaviruses, with cross 
reactivity not seen against an array of PCR positive samples for example seasonal human coronavirus OC43 
as well as non-CoV pathogens, including EBV and CMV. Subsequent testing with IgA and IgG specific ELISA 
showed some cross-reactivity with OC43 PCR positive samples and highlights the importance of assay design, 
where perhaps multiple protein targets may be required to ensure specificity for SARS-CoV-28. This urgently 
needs investigation in the western European population before widespread role out of POC SARS-CoV-2 serol-
ogy. The role of serology as an adjunct to PCR has also recently been reported, with a strong correlation seen 
between IgM and IgG and the severity of  disease10. Seroconversion for detection of IgM and IgG was seen at 
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median day 12 and 14 respectively with possibility of detection much earlier in the clinical course and is sup-
portive therefore of our findings of improving sensitivity through the first 14 days of  infection10.
If shown to be successful in the community setting POC serology testing could have significant implications 
for tackling the pandemic in resource poor settings which lack the required infrastructure for centralised molecu-
lar techniques. The benefits of utilising point-of-care testing to improve the efficiency of case identification and 
resource allocation in such circumstances has previously been discussed during the Ebola epidemic and could 
therefore be of considerable use during the SARS-CoV-2  pandemic11.
The small number of assays evaluated in this study limits the degree to which conclusions can be drawn. 
Formal power calculations have not been conducted, but with a sensitivity of 100% at greater than 14 days, 
accompanied by a margin of error of only 0.04, this exploratory study could now inform larger scale appropriately 
powered studies to fully characterise the utility of these assays in specific population groups. A greater number 
of samples are now required in order to comment reliably on sensitivity and specificity and in turn, once the 
evolving prevalence becomes clearer, the positive and negative predictive value of these tests in various groups. 
It would also be useful to conduct specificity testing using pre-pandemic serum in order to better assess pos-
sible cross-reactivity. The need for rapid initial verification of these assays to augment clinical and public health 
interventions in this pandemic does not yet enable comment on many aspects of the assays, including the IgM/
IgG relationship in the weeks and months post-infection. Awaited longitudinal studies will allow evaluation of 
assay performance at extended points in the convalescent period and better define an appropriate testing window. 
Additionally, where results are qualitative and vary in strength of response, it is unclear how test sensitivity would 
differ when (i) healthcare professionals not used to evaluating lateral flow devices or (ii) the general public read 
results. Subsequent work has since provided a model for reading SARS-CoV-2 serological assays however which 
may help with reduce any loss of sensitivity from reading by those less  experienced12. While our cohort groups 
include immunocompromised patients, pregnant individuals, and elderly patients, we are unable to sufficiently 
comment on reliability in these groups. This study is limited to evaluating reactivity in symptomatic adults with 
moderate-severe disease only and response in children has not been investigated. All positive patients in this 
study were considered to have moderate-severe infection by nature of the admitting policy of the hospital and 
evaluation in those with mild disease symptoms is needed to comment further on the population level applica-
bility of these assays.
Conclusion
SARS-CoV-2 has resulted in a global pandemic and is associated with considerable morbidity and mortality. 
Serology testing is easy-to-use at the point-of-care and its utility to support, and replace where appropriate, PCR 
could allow for a significant improvement in the understanding of the true infection burden. This will be vital 
to the control of further SARS-CoV-2 spread.
Serology testing appears to be unreliable during the early infectious period, however there may be a limited 
role for use of delayed-case identification in the appropriate context, such as in any patient that is at least 14 days 
post-symptom onset. Our data would suggest an inferiority to PCR testing in the acute phase of infection, mak-
ing them inappropriate for use in diagnosis during the infectious period. Further evaluation on a much larger 
scale is now necessary in order to reliably comment on the earliest stage post symptom onset at which testing 
can be utilised, as well as on its performance in different population groups. In the meantime, any use of rapid 
serological test kits must be interpreted with caution, particularly if symptoms are of 14 days or less duration.
Methods
A prospective single-centre study was completed at a 430-bedded acute London hospital during March 2020. 
Consecutive inpatients were selected for testing based on real-time PCR detection of SARS-CoV-2 (AusDiag-
nostics, Australia) and stratified based on duration of symptoms. Patients were included if they were admitted 
to hospital with symptoms matching the PHE case definition for  testing13, and had an accurate history recorded 
of at least 5 days of symptoms.
Exclusion criteria included all patients under 16 years old. Mild infection not requiring admittance to hospital 
were excluded. Patients that were unable to provide an accurate history or those with vague onset of symptom 
duration were also excluded in order to accurately report time-lines.
15 SARS-CoV-2 CE marked split IgM/IgG antibody tests (Core tests) were available for paired testing along-
side 15 SARS-CoV-2 CE marked total antibody rapid tests (Wantai), 15 COVID-19 CE marked split IgM/IgG 
Rapid Tests (VivaDiag), 15 COVID-19 CE marked split IgG/IgM Rapid Test Cassettes (OrientGene), and 15 
SARS-CoV-2 CE marked split IgM/IgG One Step Rapid Test Devices (Encode). Ten PCR positive and five PCR 
negative patients were selected and paired serology testing was carried out by the same three doctors (SJCP, 
AP, SJD) experienced in the use of rapid diagnostic test kits. In order to evaluate reliability of test reactivity in 
positive patients, five positive patients were evaluated between days 5–9 of symptom duration and five patients 
between days 10–14. Additionally, five patients thought to be true negative ((i) symptoms meeting the case 
definition lasting at least 5 days but no more than 10 days at presentation, (ii) at least one negative SARS-CoV-2 
PCR result, and (iii) an alternative clinical diagnosis for their symptoms) underwent paired testing in order to 
assess for false positive reactivity.
Each patient was tested by the same doctors, as per each product protocol. Test kits were then read at the des-
ignated time period as per individual protocol and a result recorded for both the appearance of a control line and 
the presence or absence of antibody test reactivity. All results were verified independently by two of the doctors.
A power-calculation for assessing significance of sensitivity analysis (with an estimate of 90%) was applied 
in analysis, setting type I error at 0.05 and type II error at 0.20. Assuming assays performed as per the manu-
facturer information it was calculated that testing 132 PCR positive individuals would be required. Using the 
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same inclusion criteria a further 200 patients were evaluated using the COVID-19 IgG/IgM Rapid Test Cassettes 
(OrientGene). Patient history from both the Emergency Department assessment and the admission clerking were 
carefully evaluated and patients excluded if there was doubt over exact symptom onset, including those patients 
with vague history of onset, presenting with confusion, or following early intubation with an incomplete history. 
Patients were stratified based on consecutive PCR positive results to one of 3 time interval groups since symptom 
onset, encompassing 83% of SARS-CoV-2 positive cumulative inpatients at the time of the study period end-
point. 50 PCR positive patients were stratified to the 5–9 post-symptom onset group, 50 patients to the 10–14 day 
post-symptom onset group and 50 patients at greater than 14 days since symptom onset. An additional 50 patients 
were selected with a presumed negative diagnosis with a negative SARS-CoV-2 PCR result, admitted with an 
acute surgical complication or had a fever with an alternative, non-respiratory primary diagnosis.
Prevalence estimates at the time of the study, provided by modelling by the MRC Centre of Global Infectious 
Diseases Analysis  report6, were used to estimate a PPV if these assays were to be deployed for use in the general 
population.
Five additional test cassettes were used to evaluate possible anticipated end-user difficulties. Three test cas-
settes were employed to retest a patient with a positive result to comment on reproducibility. One test cassette was 
completed with too little blood, failing to fill the pipette to the indicated line and one test cassette was completed 
with too much blood, by over-filling the well.
Consent. This study was approved by the Chelsea & Westminster NHS Foundation Trust COVID testing 
committee. The study was reviewed by the Chelsea & Westminster NHS Foundation Trust Research and Devel-
opment Office and deemed a verification of a CE marked in vitro diagnostic test, therefore the need individual 
informed consent was waived. Aggregated data was analysed in accordance to the UK Secretary of State for 
Health and Social Care general notice that under the Health Service Control of Patient Information Regulations 
(2002) patient data for a COVID-19 purposes may be used for research. The study was conducted in accordance 
with relevant guidelines and regulations including the Declaration of Helsinki.
Data availability
The data analysed during the current study and further details on the assays are available from the corresponding 
author (LSPM; l.moore@imperial.ac.uk) on reasonable request, as long as this meets local ethical and research 
governance criteria.
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